IBA
IBA Aamal Mubtakara Advertising is a privately held advertising and marketing services firm founded in 2011, headquartered in Dubai, United Arab Emirates, serving the UAE and regional market with 101-250 employees.
- Company typePrivate
- Founded2011
- HeadquartersDubai, United Arab Emirates
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
IBA firmographics
Firmographics- Name
- IBA
- Website
- https://i-iba.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- IBA Aamal Mubtakara Advertising is a privately held advertising and marketing services firm founded in 2011, headquartered in Dubai, United Arab Emirates, serving the UAE and regional market with 101-250 employees.
- Ownership category
- akta.pro rank
IBA industry classification
Industry- Product category
- Nuclear Medicine Equipment
- NAICS
- Irradiation Apparatus Manufacturing (334517), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD)
- akta.pro secondary industries
- Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI), Radiation Detection Instruments & Systems (Portal monitors, spectrometers, contamination monitors) (EUAKAIAK)
Keywords
Where IBA is headquartered
LocationHeadquarters
- HQ city
- Dubai
- HQ country
- United Arab Emirates
- HQ region
- Middle East
Offices1 record
Markets served
IBA business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales
IBA product offering
Product offeringCore offering
IBA develops and supplies particle accelerator technology used in nuclear medicine applications, enabling radiopharmaceutical production for diagnostic imaging and cancer therapy. The company is expanding its radiochemistry and radiopharmaceutical development capabilities through acquisitions to support personalized cancer diagnostics and treatment workflows for healthcare and research customers.
Product overview
IBA is a Belgium-based company specializing in particle accelerator technology. The company operates primarily in the nuclear medicine sector, providing solutions for personalized cancer diagnostics and therapy. IBA's portfolio centers on particle accelerator systems and related technologies for medical applications, including radiochemistry capabilities for producing radiopharmaceuticals. The recent acquisition of ORA (a radiochemistry company) in December 2025 strengthens IBA's position in nuclear medicine and expands its offerings in personalized cancer diagnostics and therapy. No specific named products or modules are detailed in the available source data.
Differentiator
Problem solved
Functional benefit
Products and services
- Particle Accelerator Systems for Nuclear Medicine
- Radiochemistry and Radiopharmaceutical Development Services
Companies that use IBA
Customer profileSegments1 record
Ideal customer profiles2 records
IBA technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
IBA partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- ORAcoreIBA acquired ORA, a Belgian radiochemistry company, as part of its strategic expansion in nuclear medicine. The acquisition aims to enhance IBA's offerings in personalized cancer diagnostics and therapy. The deal is valued at €15-20 million and is financially accretive without impacting IBA's 2025 outlook.
Scale indicators1 record
IBA competitors and assessment
Company assessmentBroad incumbents
- Siemens Healthineers: Diversified medical imaging and cancer care major with a growing nuclear medicine and radiopharma portfolio. Comparable as a large-scale provider competing across diagnostics, imaging, and therapy where IBA operates.
- GE HealthCare: Global medical imaging and pharmaceutical diagnostics player with strong nuclear medicine and PET imaging offerings. Competes with IBA in the broader cancer diagnostics ecosystem.
- Philips: Major healthcare technology company with imaging and diagnostic solutions serving oncology workflows. Comparable as a broad incumbent addressing similar hospital and nuclear medicine end markets.
- Varian (a Siemens Healthineers company): Radiation oncology and proton therapy specialist now part of Siemens Healthineers. Direct overlap with IBA in particle therapy systems for cancer treatment.
- Elekta: Radiotherapy and radiosurgery equipment provider competing with IBA in advanced cancer therapy hardware used by hospitals and cancer centers.
- Bracco Imaging: Diagnostic imaging company with a strong contrast media and radiopharmaceutical portfolio. Adjacent peer in the broader nuclear medicine and oncology diagnostics space.
Direct peers
- Curium: Global nuclear medicine and radiopharmaceutical company producing diagnostic and therapeutic isotopes. Directly comparable as a radiopharma player serving similar end customers as IBA.
- Lantheus Holdings: Radiopharmaceutical-focused company developing and commercializing diagnostic and therapeutic agents for oncology. Comparable to IBA's cancer diagnostics and therapy focus.
- Nordion (Sotera Health): Provider of Cobalt-60 and other isotopes used in medical and industrial sterilization and therapy. Comparable as a nuclear/isotope supply chain peer relevant to IBA's radioisotope positioning.
Emerging players
- Telix Pharmaceuticals: Radiopharmaceutical company focused on diagnostic and therapeutic products across prostate, kidney, and brain cancers. Competes with IBA's radiopharma ambitions following the ORA acquisition.
Market position
Strengths4 records
Weaknesses4 records
Key risks4 records
Key highlights4 records
Customer concentration
IBA social profiles
Digital presenceIBA financial estimates
Financial estimateRevenue estimate
Valuation estimate
IBA leadership team
Management profileNumber of profiles
Profiles1 record
IBA subsidiaries and ownership
Company hierarchySubsidiaries1 record
IBA funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
IBA M&A and investment
M&A and investmentM&A
Investments3 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about IBA
What does IBA do?
IBA develops and supplies particle accelerator technology used in nuclear medicine applications, enabling radiopharmaceutical production for diagnostic imaging and cancer therapy. The company is expanding its radiochemistry and radiopharmaceutical development capabilities through acquisitions to support personalized cancer diagnostics and treatment workflows for healthcare and research customers.
When was IBA founded?
IBA was founded in 2011. It employs 101 to 250 people.
Where is IBA based?
IBA is headquartered in Dubai, United Arab Emirates, in the Middle East region.
Who are IBA's main competitors?
Broad incumbents on record are Siemens Healthineers, GE HealthCare, Philips, Varian (a Siemens Healthineers company), Elekta and Bracco Imaging. Direct peers are Curium, Lantheus Holdings and Nordion (Sotera Health). Telix Pharmaceuticals is listed as an emerging player.
Does IBA have an API?
No public API is recorded for IBA.
What industry is IBA in?
IBA's product category is Nuclear Medicine Equipment. Its primary akta.pro industry code is HLAIAGAD, Radioisotope Production (Reactor/Cyclotron/Gamma), with a secondary code of HLAIAGAI, Nuclear Medicine Clinical Services & Therapy Centers. Its NAICS code is 334517 and its SIC code is 3844.